Shanghai Haoyuan Chemexpress Co (SHSE:688131) Total Liabilities : ¥1,962 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Shanghai Haoyuan Chemexpress Co Total Liabilities?

Shanghai Haoyuan Chemexpress Co's Total Liabilities for the quarter that ended in Sep. 2024 was ¥1,962 Mil.

Shanghai Haoyuan Chemexpress Co's quarterly Total Liabilities declined from Mar. 2024 (¥1,758.12 Mil) to Jun. 2024 (¥1,729.75 Mil) but then increased from Jun. 2024 (¥1,729.75 Mil) to Sep. 2024 (¥1,961.78 Mil).

Shanghai Haoyuan Chemexpress Co's annual Total Liabilities increased from Dec. 2021 (¥548.11 Mil) to Dec. 2022 (¥1,265.78 Mil) and increased from Dec. 2022 (¥1,265.78 Mil) to Dec. 2023 (¥1,665.93 Mil).

Shanghai Haoyuan Chemexpress Co Total Liabilities Historical Data

The historical data trend for Shanghai Haoyuan Chemexpress Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Haoyuan Chemexpress Co Total Liabilities Chart

Shanghai Haoyuan Chemexpress Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

141.44

419.84

548.11

1,265.78

1,665.93

Shanghai Haoyuan Chemexpress Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															1,642.89	1,665.93	1,758.12	1,729.75	1,961.78

Shanghai Haoyuan Chemexpress Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shanghai Haoyuan Chemexpress Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1163.812	+	(398.095	+	104.023
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,666

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	4192.208	-	2526.278
	=	1,666

Shanghai Haoyuan Chemexpress Co's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1210.004	+	(635.853	+	115.925
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,962

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	4683.503	-	2721.72
	=	1,962

Shanghai Haoyuan Chemexpress Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shanghai Haoyuan Chemexpress Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Haoyuan Chemexpress Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Haoyuan Chemexpress Co Ltd (SHSE:688131) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

No. 2, Lane 720, Cailun Road, Room 501, Pilot Free Trade Zone, Shanghai, CHN, 201203

Website

http://www.chemexpress.com.cn

Shanghai Haoyuan Chemexpress Co Ltd focuses on providing small molecule and new modalities CDMO services for both pharmaceutical and biotech clients. The company's comprehensive CRO & CDMO platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products. It is a one-stop service platform to support client's projects from early drug discovery, process development to commercialization. The company is committed to delivering high-quality products and CMC services to clients across the entire life cycle of drug development.

Executives

Mei Kui

Core technical personnel

Shanghai Haoyuan Chemexpress Co Headlines

No Headlines